Results of FISH, Southern blot, Q-RT-PCR in 21 CML patients in CCR at the time of study
| Patient No. . | No. of Metaphases Analyzed During Remission . | FISH BCR-ABL Fusion Signal . | Southern Blot (Percentage of Rearranged DNA Fragments) . | Q-RT-PCR BCR-ABL/ABL Ratio . |
|---|---|---|---|---|
| 1 | 1047 | 2% (BM) | Negative | <0.002% |
| 2 | 882 | 1% (Blood) | Negative | <0.002% |
| 3 | 263 | 2% (BM) | Negative | <0.002% |
| 4 | 191 | 6% (BM) | Positive (<5%) | 0.12% |
| 5 | 62 | 7% (BM) | Positive (5-10%) | 0.2% |
| 6 | 508 | 2% (BM) | Positive (<5%) | 0.006% |
| 7 | 235 | 12% (Blood) | ND | <0.002% |
| 8 | 229 | 9% (BM) | Negative | 0.02% |
| 9 | 395 | 3% (Blood) | Positive (<5%) | 0.02% |
| 10 | 138 | 7% (BM) | Positive (<5%) | 0.17% |
| 11 | 255 | 9% (BM) | Negative | <0.002% |
| 12 | 94 | 5% (BM) | ND | <0.002% |
| 13 | 306 | 6% (Blood) | Negative | <0.002% |
| 14 | 276 | 8% (Blood) | Positive (<5%) | <0.002% |
| 15 | 100 | 6% (Blood) | ND | <0.002% |
| 16 | 74 | 6% (BM) | ND | <0.002% |
| 17 | 133 | 11% (Blood) | ND | <0.002% |
| 18 | 219 | 7% (BM) | ND | <0.002% |
| 19 | 111 | 3% (BM) | ND | <0.002% |
| 20 | 284 | 11% (BM) | Positive (<5%) | <0.002% |
| 21 | 175 | 7% (BM) | ND | <0.002% |
| Patient No. . | No. of Metaphases Analyzed During Remission . | FISH BCR-ABL Fusion Signal . | Southern Blot (Percentage of Rearranged DNA Fragments) . | Q-RT-PCR BCR-ABL/ABL Ratio . |
|---|---|---|---|---|
| 1 | 1047 | 2% (BM) | Negative | <0.002% |
| 2 | 882 | 1% (Blood) | Negative | <0.002% |
| 3 | 263 | 2% (BM) | Negative | <0.002% |
| 4 | 191 | 6% (BM) | Positive (<5%) | 0.12% |
| 5 | 62 | 7% (BM) | Positive (5-10%) | 0.2% |
| 6 | 508 | 2% (BM) | Positive (<5%) | 0.006% |
| 7 | 235 | 12% (Blood) | ND | <0.002% |
| 8 | 229 | 9% (BM) | Negative | 0.02% |
| 9 | 395 | 3% (Blood) | Positive (<5%) | 0.02% |
| 10 | 138 | 7% (BM) | Positive (<5%) | 0.17% |
| 11 | 255 | 9% (BM) | Negative | <0.002% |
| 12 | 94 | 5% (BM) | ND | <0.002% |
| 13 | 306 | 6% (Blood) | Negative | <0.002% |
| 14 | 276 | 8% (Blood) | Positive (<5%) | <0.002% |
| 15 | 100 | 6% (Blood) | ND | <0.002% |
| 16 | 74 | 6% (BM) | ND | <0.002% |
| 17 | 133 | 11% (Blood) | ND | <0.002% |
| 18 | 219 | 7% (BM) | ND | <0.002% |
| 19 | 111 | 3% (BM) | ND | <0.002% |
| 20 | 284 | 11% (BM) | Positive (<5%) | <0.002% |
| 21 | 175 | 7% (BM) | ND | <0.002% |
For each patient, FISH, Southern blot (when done), and Q-RT-PCR experiments were simultaneously performed. FISH was carried out on bone marrow (BM) or blood samples. Southern blot and Q-RT-PCR were performed on blood samples. Patients 1-11 were treated with IFN-α and patients 12-21 received allogeneic BMT. IFN indicates interferon; BMT, bone marrow transplantation; FISH, fluorescent in situ hybridization; Q-RT-PCR, quantitative reverse transcription-polymerase chain reaction; CML, chronic myeloid leukemia; CCR, complete cytogenetic remission; ND, not done.